High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp

Gisselbrecht, C; Canals, C; Mounier, N; Foa, R; Conde, E; Maertens, Johan; Rambaldi, A; Masszi, T; Luan, JJ; Crawley, C; Cook, G; Attal, M; Pfreundschuh, M; Harousseau, JL; Sureda, A

Haematologica-the hematology journal

High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp

Author:

Gisselbrecht, C

Canals, C ; Mounier, N ; Foa, R ; Conde, E ; Maertens, Johan ; Rambaldi, A ; Masszi, T ; Luan, JJ ; Crawley, C ; Cook, G ; Attal, M ; Pfreundschuh, M ; Harousseau, JL ; Sureda, A

Keywords:

Science & Technology, Life Sciences & Biomedicine, Hematology, 1102 Cardiorespiratory Medicine and Haematology, Immunology, 3201 Cardiovascular medicine and haematology

Haematologica-the hematology journal High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp

Author:

Keywords:

Haematologica-the hematology journal

High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp